In January of this year, the FDA noted that it had "received adverse event reports after patients used compounded semaglutide" and that "patients should not use a compounded drug if an approved drug is available to treat a patient." In July, the agency followed up with a notice that it had "received reports of adverse events, some requiring hospitalization, that may be related to overdoses due to dosing errors associated with compounded semaglutide injectable products." And in August, Eli Lilly, the maker of Zepbound and Mounjaro, sent a series of cease-and-desist letters to providers urging them to stop prescribing compounded versions of those drugs
Again, intermittent fasting isnt a magic solution for weight loss, and its not right for everyone
TMX MoneyMenu
The primary endpoint was change in body weight from baseline to 13 weeks
The timeline from prediabetes to diabetes is thought to be 3-5 years on average, with as much as 25-50% of prediabetics becoming diabetic
B12 is a plays a fundamental role in providing energy for the brain to operate smoothly, and is part of the production of red blood cells